Details of the Drug

General Information of Drug (ID: DMI6E0R)

Drug Name
Midostaurin
Synonyms
PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Systemic mastocytosis 2A21.0 Approved [2]
Chronic myelomonocytic leukaemia 2A40 Phase 2 [3]
Colorectal cancer 2B91.Z Phase 1 [3]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EX10: Midostaurin
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 570.6
Logarithm of the Partition Coefficient (xlogp) 4.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 21 hours [4]
Metabolism
The drug is metabolized via the hepatic CYP3A4 [5]
Vd
The volume of distribution (Vd) of drug is 95.2 L []
Chemical Identifiers
Formula
C35H30N4O4
IUPAC Name
N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
Canonical SMILES
C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
InChI
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
InChIKey
BMGQWWVMWDBQGC-IIFHNQTCSA-N
Cross-matching ID
PubChem CID
9829523
ChEBI ID
CHEBI:63452
CAS Number
120685-11-2
UNII
ID912S5VON
DrugBank ID
DB06595
TTD ID
D07NVU
VARIDT ID
DR01370
INTEDE ID
DR1090
ACDINA ID
D00431
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [6]
Protein kinase C gamma (PRKCG) TTRFOXJ KPCG_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [9]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [10]
Fibroblast growth factor receptor 3 (FGFR3) OTSAXDIL FGFR3_HUMAN Gene/Protein Processing [11]
Glycophorin-A (GYPA) OTABU4YV GLPA_HUMAN Gene/Protein Processing [12]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Drug Response [13]
Thrombopoietin receptor (MPL) OTZEN192 TPOR_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fms-like tyrosine kinase 3 (FLT-3) DTT FLT3 2.11E-01 -0.05 -0.16
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 -1.1941 0.8279 -2.0594 9.4862
G-292 clone A141B1 GDSC1 -3.9153 4.7201 -6.5284 43.8689
CHSA0108 GDSC1 -3.0984 0.6429 -3.8682 31.3399
CHSA8926 GDSC1 -2.9367 9.0364 -7.6914 41.1767
NY GDSC1 -2.7808 0.721 -3.5695 27.8141
HuO-3N1 GDSC1 -2.609 3.6242 -4.7415 32.7314
MHH-ES-1 GDSC1 -2.4046 -0.306 -2.7551 20.3637
EW-16 GDSC1 -1.9184 0.2455 -2.4752 15.8635
EW-18 GDSC1 -1.5948 0.2618 -2.1591 11.966
NOS-1 [Human HNSCC] GDSC1 -1.5164 2.5836 -3.2179 19.4355
ES7 GDSC1 -1.4627 0.9136 -2.3461 12.8171
ES1 GDSC1 -1.4503 -0.5998 -1.6254 7.2732
EW-13 GDSC1 -1.4122 0.186 -1.9458 9.513
U2OS GDSC1 -1.4103 4.7899 -4.222 24.9925
MG-63 GDSC1 -1.407 2.1585 -2.9093 16.813
HOS GDSC1 -1.4019 0.2887 -1.9854 9.773
CHSA0011 GDSC1 -1.3859 1.9809 -2.8024 15.9464
SK-PN-DW GDSC1 -1.2822 0.7439 -2.0968 10.1329
HuO9 GDSC1 -1.2721 1.2075 -2.3172 11.8066
SK-ES-1 GDSC1 -1.192 -0.0871 -1.6054 5.9284
EW-1 GDSC1 -1.0149 1.4128 -2.1962 9.8726
H-EMC-SS GDSC1 -0.8293 1.6618 -2.1677 8.9852
A-673 GDSC1 -0.8272 1.1824 -1.9267 7.0897
EW-7 GDSC1 -0.7649 2.1034 -2.3364 10.0733
ES8 GDSC1 -0.6703 2.1427 -2.2812 9.3277
CAL-78 GDSC1 -0.4896 10.4058 -6.2598 29.7483
ES4 GDSC1 -0.4648 2.4298 -2.2663 8.5532
ES5 GDSC1 -0.0064 5.3268 -3.3527 14.8751
ES6 GDSC1 0.0121 4.1569 -2.7649 10.8144
SJSA-1 GDSC1 0.2074 5.3925 -3.2282 13.4178
EW-3 GDSC1 0.4613 5.5505 -3.1249 12.0114
EW-24 GDSC1 0.5906 2.4997 -1.6376 1.6748
EW-11 GDSC1 1.1009 7.6789 -3.7106 13.9339
TC-71 GDSC1 1.1802 2.6811 -1.4539 0.3612
CAL-72 GDSC1 2.0886 14.2247 -6.1905 22.6206
SaOS-2 GDSC1 4.3591 23.361 -9.0282 25.7118
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 149 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JM1 GDSC1 -1.4518 -0.1802 -1.812 8.6715
MOLM-13 GDSC1 -5.7107 -1.9198 -5.9183 57.6041
MV4-11 GDSC1 -5.5828 -3.1343 -5.6177 57.2788
NKM-1 GDSC1 -4.6646 -0.5697 -5.1171 47.0257
EoL-1 GDSC1 -4.3695 -2.4796 -4.4018 42.6991
Kasumi-1 GDSC1 -4.115 -0.6378 -4.4975 40.9985
NALM-6 GDSC1 -3.1656 -1.3585 -3.2718 28.1742
MOLP-8 GDSC1 -3.0038 -0.1968 -3.4388 28.2753
Mono-Mac-6 GDSC1 -2.841 12.6744 -9.4054 42.7231
ALL-PO GDSC1 -2.7339 -1.1237 -2.8547 22.886
NK-92MI GDSC1 -2.6631 0.1779 -3.2198 24.9445
GDM-1 GDSC1 -2.5872 0.2682 -3.177 24.2492
697 GDSC1 -2.5727 -1.4029 -2.6223 20.4035
SIG-M5 GDSC1 -2.2826 4.5037 -4.8629 31.6631
SU-DHL-10 GDSC1 -2.2731 1.2602 -3.2943 23.41
KE-37 GDSC1 -2.2278 -1.0866 -2.312 16.3227
SU-DHL-16 GDSC1 -2.1712 -0.9048 -2.2984 15.9064
ALL-SIL GDSC1 -2.0999 -0.4424 -2.3774 16.0687
OCI-Ly19 GDSC1 -2.0348 0.0996 -2.5303 16.8402
SU-DHL-5 GDSC1 -1.9051 -1.0832 -1.9614 12.1066
YT GDSC1 -1.8674 1.1628 -2.8507 18.3887
GA-10 GDSC1 -1.837 -1.0708 -1.8901 11.2353
RS4;11 GDSC1 -1.8195 0.0279 -2.2777 13.9191
P32/ISH GDSC1 -1.8123 -0.2844 -2.1357 12.8352
P30/OHK GDSC1 -1.7873 0.4963 -2.4584 15.1162
SU-DHL-6 GDSC1 -1.7241 -0.642 -1.8998 10.6746
KG-1 GDSC1 -1.6365 0.2188 -2.1801 12.3177
OCI-AML-2 GDSC1 -1.6301 -1.0263 -1.6752 8.5971
BC-1 GDSC1 -1.5989 0.1904 -2.1297 11.7618
TUR GDSC1 -1.5702 0.6619 -2.3254 13.1242
OCI-AML-5 GDSC1 -1.5331 0.1047 -2.0249 10.6631
ST486 GDSC1 -1.5155 0.751 -2.3164 12.8157
CCRF-CEM GDSC1 -1.4932 0.2739 -2.0658 10.7946
SR GDSC1 -1.481 0.3746 -2.1022 11.0194
Karpas-231 GDSC1 -1.4783 -0.2992 -1.7846 8.5909
QIMR-WIL GDSC1 -1.4475 0.2045 -1.9887 9.9995
P12-Ichikawa GDSC1 -1.4368 -0.812 -1.5287 6.508
Karpas-620 GDSC1 -1.4261 1.0769 -2.3922 13.0165
ATN-1 GDSC1 -1.4023 0.3656 -2.0229 10.0641
L-540 GDSC1 -1.3902 1.1375 -2.3892 12.844
A3/Kawakami GDSC1 -1.3781 0.5866 -2.1076 10.6163
BL-41 GDSC1 -1.3669 -0.0043 -1.8113 8.2783
WSU-NHL GDSC1 -1.3622 0.5709 -2.0852 10.3758
Reh GDSC1 -1.3481 0.152 -1.8683 8.6353
ML-2 GDSC1 -1.3042 0.2693 -1.8839 8.5669
Ramos.2G6.4C10 GDSC1 -1.2958 0.0669 -1.7777 7.7078
PF-382 GDSC1 -1.2688 0.508 -1.9683 9.0759
BV-173 GDSC1 -1.2489 -0.1977 -1.6054 6.1726
H9 GDSC1 -1.2464 0.2407 -1.8163 7.7978
SUP-B15 GDSC1 -1.201 0.0479 -1.6799 6.5462
Karpas-45 GDSC1 -1.1631 1.2119 -2.2231 10.6444
MEG-01 GDSC1 -1.1432 0.2845 -1.7443 6.8138
MOLT-4 GDSC1 -1.1382 1.0422 -2.1168 9.7172
A4/Fukuda GDSC1 -1.1332 2.2604 -2.7204 14.3358
Karpas-422 GDSC1 -1.1206 -0.4423 -1.3656 3.7629
CESS GDSC1 -1.1171 0.7545 -1.955 8.3663
KOPN-8 GDSC1 -1.1059 0.2785 -1.7083 6.3837
MOLT-16 GDSC1 -1.0944 0.6317 -1.8741 7.6431
HL-60 GDSC1 -1.0906 -0.256 -1.4294 4.1347
SU-DHL-8 GDSC1 -1.0905 0.7474 -1.9284 8.0555
Daudi GDSC1 -1.0844 0.9931 -2.0457 8.9536
SUP-T1 GDSC1 -1.0768 2.1064 -2.5953 13.1812
BE-13 GDSC1 -1.0662 0.186 -1.6273 5.5929
BC-3 GDSC1 -1.0438 1.4788 -2.2536 10.4284
DoHH2 GDSC1 -1.0182 -0.0712 -1.4575 4.0721
U266B1 GDSC1 -0.9689 0.5395 -1.721 5.9678
JSC-1 GDSC1 -0.9547 0.5478 -1.7134 5.8561
DEL GDSC1 -0.9516 1.5231 -2.1984 9.6581
BALL-1 GDSC1 -0.9456 1.1094 -1.9866 7.9759
RPMI-6666 GDSC1 -0.9266 0.6795 -1.7561 6.0921
RPMI-8402 GDSC1 -0.8952 1.5484 -2.1646 9.1921
HC-1 GDSC1 -0.8774 0.7864 -1.7694 6.0247
SUP-M2 GDSC1 -0.877 0.0514 -1.4024 3.1351
NB4 GDSC1 -0.8749 1.5054 -2.1265 8.8224
NU-DUL-1 GDSC1 -0.8617 1.1685 -1.9474 7.3711
CA46 GDSC1 -0.844 3.7042 -3.2001 16.6786
VAL GDSC1 -0.8213 1.3797 -2.0204 7.8053
Loucy GDSC1 -0.7862 2.6342 -2.6184 12.2958
CTV-1 GDSC1 -0.7541 1.6494 -2.1014 8.2114
JURL-MK1 GDSC1 -0.7338 0.8758 -1.7011 5.0112
HEL GDSC1 -0.723 1.4413 -1.9734 7.107
Farage GDSC1 -0.6939 0.9953 -1.73 5.1112
DND-41 GDSC1 -0.666 1.8688 -2.1417 8.2325
MC116 GDSC1 -0.6538 2.6233 -2.5074 11.0038
Hs 445 GDSC1 -0.6503 2.9671 -2.6759 12.2559
OPM-2 GDSC1 -0.6355 1.7836 -2.0758 7.622
JJN-3 GDSC1 -0.6349 0.5806 -1.4836 3.0298
MN-60 GDSC1 -0.6261 1.6636 -2.0092 7.0739
EB2 GDSC1 -0.6114 0.9154 -1.6299 4.0851
HAL-01 GDSC1 -0.5927 1.7604 -2.0318 7.1435
Ku812 GDSC1 -0.5671 1.7106 -1.988 6.7246
GR-ST GDSC1 -0.547 2.861 -2.5424 10.913
LAMA-84 GDSC1 -0.4949 2.0139 -2.0837 7.2427
LC4-1 GDSC1 -0.4888 2.1163 -2.1297 7.5782
Granta-519 GDSC1 -0.444 1.5364 -1.8132 5.0131
KM-H2 GDSC1 -0.3895 1.8351 -1.9199 5.6737
THP-1 GDSC1 -0.3843 1.7153 -1.8581 5.1884
EM-2 GDSC1 -0.3841 2.2509 -2.1189 7.1801
DB GDSC1 -0.3809 3.9489 -2.9544 13.3749
WIL2 NS GDSC1 -0.3344 2.1954 -2.0561 6.5556
MY-M12 GDSC1 -0.3282 1.6112 -1.7694 4.3663
VL51 GDSC1 -0.3235 3.2017 -2.5415 10.1939
TK [Human B-cell lymphoma] GDSC1 -0.2828 3.1833 -2.5023 9.7779
Sc-1 GDSC1 -0.2231 5.501 -3.6031 17.1439
CTB-1 GDSC1 -0.2083 2.3069 -2.022 5.9466
K-562 GDSC1 -0.1884 1.382 -1.5725 2.5947
HH [Human lymphoma] GDSC1 -0.159 2.4463 -2.0552 6.0636
ARH-77 GDSC1 -0.131 2.098 -1.8703 4.6142
SUP-HD1 GDSC1 -0.1126 3.0256 -2.3029 7.7909
OCI-M1 GDSC1 -0.0669 1.3968 -1.5088 1.9206
IM-9 GDSC1 -0.0577 3.2006 -2.3493 7.9832
Jiyoye GDSC1 -0.0283 2.3879 -1.9405 4.8768
EHEB GDSC1 -0.0198 3.0405 -2.2459 7.1126
SU-DHL-1 GDSC1 0.0559 2.0646 -1.738 3.2334
KMOE-2 GDSC1 0.079 2.6769 -2.0074 5.1055
WSU-DLCL2 GDSC1 0.0851 4.9545 -3.1024 12.9425
L-363 GDSC1 0.1233 3.0169 -2.1391 5.9559
OCI-AML-3 GDSC1 0.1678 2.1543 -1.7131 2.8371
NOMO-1 GDSC1 0.2434 1.7961 -1.5167 1.467
MLMA GDSC1 0.2472 3.3426 -2.2124 6.1836
EJM GDSC1 0.2729 1.9794 -1.5792 1.7936
KMS-12-BM GDSC1 0.2851 3.561 -2.2909 6.6558
PL-21 GDSC1 0.3998 2.4996 -1.7363 2.5647
L-428 GDSC1 0.4003 3.1848 -2.0433 4.63
KCL-22 GDSC1 0.4138 3.2 -2.0421 4.5922
Namalwa GDSC1 0.499 2.7171 -1.7773 2.6553
MHH-PREB-1 GDSC1 0.5485 4.9552 -2.7793 9.4414
LP-1 GDSC1 0.5563 2.2952 -1.5702 1.3493
SU-DHL-4 GDSC1 0.5658 2.0407 -1.4645 0.8158
RPMI-8226 GDSC1 0.6095 2.4804 -1.6204 1.5543
JVM-2 GDSC1 0.6167 3.8277 -2.2073 5.3012
HDLM-2 GDSC1 0.6237 5.6776 -3.0743 11.2368
SCC-3 GDSC1 0.6559 1.9854 -1.4056 0.5016
AMO1 GDSC1 0.713 2.3078 -1.504 0.8563
HT GDSC1 0.7167 6.2359 -3.2793 12.3195
P31/FUJ GDSC1 0.7614 1.9674 -1.3579 0.2889
SK-MM-2 GDSC1 0.7755 7.4042 -3.8034 15.3405
U-698-M GDSC1 0.9732 2.8083 -1.5847 0.9772
RL GDSC1 0.9984 2.3642 -1.4097 0.3229
JVM-3 GDSC1 1.0438 3.0547 -1.6497 1.2066
ROS-50 GDSC1 1.0562 5.5414 -2.7284 7.8708
KY821 GDSC1 1.0873 2.5709 -1.4498 0.3941
ME1 GDSC1 1.0895 2.4328 -1.4001 0.2605
Raji GDSC1 1.1561 2.691 -1.4666 0.4091
RC-K8 GDSC1 1.2475 2.7896 -1.4671 0.3668
L-1236 GDSC1 1.3146 3.6102 -1.7473 1.3944
Karpas-299 GDSC1 1.3655 2.6463 -1.3751 0.1323
DG-75 GDSC1 1.4489 3.3541 -1.5932 0.6494
RPMI-8866 GDSC1 1.8963 3.6686 -1.5364 0.286
⏷ Show the Full List of 149 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-50 GDSC1 -2.1179 3.4005 -4.1704 27.7901
HCE-4 GDSC1 -1.4589 2.4396 -3.0951 18.3487
KYSE-220 GDSC1 -1.3188 0.032 -1.7826 7.8457
TE-12 GDSC1 -0.9412 2.1803 -2.5184 12.094
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1 -0.0094 2.7163 -2.0838 5.8843
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CHP-212 GDSC1 -3.1363 -0.9363 -3.3427 28.4507
SK-N-MC-IXC GDSC1 -2.8 -1.6006 -2.8367 23.1609
SK-N-SH GDSC1 -2.477 -0.4856 -2.7672 20.8396
NB69 GDSC1 -2.3722 0.9314 -3.2433 23.5697
GI-ME-N GDSC1 -2.2433 2.9804 -4.0836 27.9352
IMR-5 GDSC1 -1.4026 -0.247 -1.7323 7.8385
KP-N-YS GDSC1 -1.3289 0.5561 -2.0471 9.9394
SJNB-7 GDSC1 -1.0013 0.9223 -1.9396 7.8088
TGW GDSC1 -0.8491 0.5681 -1.6378 4.8921
SJNB-5 GDSC1 -0.7683 0.7259 -1.6532 4.7472
SJNB-6 GDSC1 -0.7432 2.1383 -2.3364 9.9991
NB(TU)1 GDSC1 -0.7079 1.5776 -2.0294 7.4954
SK-N-DZ GDSC1 -0.7041 1.228 -1.853 6.1038
SJNB-13 GDSC1 -0.6513 2.1671 -2.2785 9.2437
SJNB-14 GDSC1 -0.5101 1.4328 -1.8098 5.176
MHH-NB-11 GDSC1 -0.419 1.737 -1.8931 5.5526
KP-N-YN GDSC1 -0.4046 1.6982 -1.864 5.2899
Kelly GDSC1 -0.3804 1.2293 -1.6222 3.401
CHP-126 GDSC1 -0.2083 1.8105 -1.7848 4.1749
NH-12 GDSC1 -0.0715 6.3314 -3.8985 18.4045
SJNB-17 GDSC1 -0.0355 2.4092 -1.9552 5.0029
GOTO GDSC1 0.0951 2.8638 -2.0851 5.632
SJNB-10 GDSC1 0.1077 1.8244 -1.6004 2.2034
SiMa GDSC1 0.3422 4.2762 -2.5932 8.6756
SK-N-FI GDSC1 0.9858 2.6904 -1.5343 0.7536
SK-N-AS GDSC1 0.9862 2.4662 -1.451 0.452
SJNB-12 GDSC1 1.1638 7.9515 -3.7987 14.2779
LA-N-6 GDSC1 1.196 2.8184 -1.4971 0.4811
SK-N-BE(2)-M17 GDSC1 1.2867 2.7528 -1.4396 0.2805
NB1 GDSC1 1.517 3.0261 -1.451 0.228
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1 -2.3261 -0.1607 -2.7277 19.7533
Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-51 GDSC1 -3.4776 -1.9962 -3.5093 31.5956
BT-549 GDSC1 -2.4752 1.0477 -3.3999 25.1221
HCC1395 GDSC1 -2.3984 13.8688 -9.6083 41.6135
CAL-120 GDSC1 -2.1657 1.2458 -3.1813 22.1246
MDA-MB-468 GDSC1 -2.0414 -1.1874 -2.0874 13.7414
MDA-MB-231 GDSC1 -1.7314 3.3016 -3.7669 23.8386
EFM-19 GDSC1 -1.6633 22.102 -13.086 42.5087
MCF-7 GDSC1 -1.6543 0.1021 -2.144 12.1278
MRK-nu-1 GDSC1 -1.541 0.3509 -2.1487 11.6431
DU4475 GDSC1 -1.3706 3.6986 -3.6434 21.578
EFM-192A GDSC1 -1.3098 6.2261 -4.8523 27.5511
HCC38 GDSC1 -1.2708 1.88 -2.6503 14.3489
MDA-MB-157 GDSC1 -1.1237 9.6053 -6.3835 32.1394
HCC1599 GDSC1 -1.0177 0.616 -1.8004 6.7723
CAL-85-1 GDSC1 -0.9697 1.648 -2.2759 10.3287
CAL-148 GDSC1 -0.9671 0.3682 -1.6339 5.2743
HCC1569 GDSC1 -0.7395 2.1936 -2.3611 10.1771
HCC70 GDSC1 -0.733 0.9284 -1.7265 5.2076
BT-20 GDSC1 -0.7299 0.8327 -1.6768 4.8094
JIMT-1 GDSC1 -0.7295 0.7204 -1.621 4.3719
HCC1187 GDSC1 -0.7223 3.4287 -2.9636 14.5972
OCUB-M GDSC1 -0.4925 1.9853 -2.0679 7.1134
Hs 578T GDSC1 -0.2605 2.2588 -2.0348 6.1865
T-47D GDSC1 -0.1818 2.4402 -2.068 6.2209
HDQ-P1 GDSC1 -0.1475 2.3495 -2.0011 5.6277
HCC1806 GDSC1 -0.0932 2.4549 -2.015 5.5898
AU565 GDSC1 -0.0299 2.4499 -1.9708 5.1033
HCC2157 GDSC1 -0.0025 5.7931 -3.5798 16.2953
MDA-MB-175-VII GDSC1 0.1854 3.5627 -2.3574 7.3898
COLO 824 GDSC1 0.2132 3.5505 -2.3331 7.1416
HCC1428 GDSC1 0.2399 3.279 -2.1871 6.0188
CAMA-1 GDSC1 0.383 2.6398 -1.8073 3.0568
HCC1500 GDSC1 0.4014 3.1129 -2.0098 4.3945
ZR-75-30 GDSC1 0.4247 3.2631 -2.0645 4.7245
Evsa-T GDSC1 0.8312 2.5493 -1.5461 0.9357
HCC1937 GDSC1 0.8819 2.8978 -1.661 1.4367
HCC1419 GDSC1 1.0639 2.3683 -1.3869 0.2391
HCC2218 GDSC1 1.0944 2.9036 -1.5696 0.8105
UACC-812 GDSC1 1.1638 2.8964 -1.5384 0.6407
MFM-223 GDSC1 1.2262 2.6576 -1.4285 0.2767
MDA-MB-436 GDSC1 1.2993 3.1993 -1.5961 0.76
MDA-MB-415 GDSC1 1.3343 3.3368 -1.6333 0.8782
BT-474 GDSC1 1.4164 2.7756 -1.4011 0.1626
HCC1954 GDSC1 1.4789 3.4338 -1.6105 0.6906
MDA-MB-361 GDSC1 1.5071 3.3956 -1.5854 0.5882
BT-483 GDSC1 1.5514 7.3875 -3.2774 10.2498
UACC-893 GDSC1 1.5865 3.4655 -1.5799 0.5271
MDA-MB-453 GDSC1 1.6266 3.7565 -1.6706 0.8078
MDA-MB-330 GDSC1 1.8844 6.471 -2.6635 5.7888
⏷ Show the Full List of 49 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D-336MG GDSC1 -3.462 0.8823 -4.3487 35.8785
YH-13 GDSC1 -3.221 1.0345 -4.1603 33.5501
KS-1 [Human Krukenberg tumour] GDSC1 -2.8486 0.9686 -3.7464 29.2306
42-MG-BA GDSC1 -2.7371 0.7037 -3.5169 27.2521
H4 GDSC1 -2.6606 -0.7271 -2.8857 22.6737
Hs 683 GDSC1 -2.6091 -0.5741 -2.8796 22.3427
SK-MG-1 GDSC1 -2.6013 0.1367 -3.138 24.063
CAS-1 GDSC1 -2.6009 -0.047 -3.0643 23.561
8-MG-BA GDSC1 -2.4228 2.9547 -4.2418 29.6055
D-423MG GDSC1 -2.4039 1.0875 -3.3459 24.4064
T98G GDSC1 -2.3267 -0.4725 -2.6098 18.9243
YKG-1 GDSC1 -2.2254 -0.3389 -2.551 17.9679
ONS-76 GDSC1 -2.1945 -0.0472 -2.6346 18.4052
LN-18 GDSC1 -2.1193 -1.0788 -2.1957 14.9157
NMC-G1 GDSC1 -2.082 -0.6853 -2.2707 15.2191
MOG-G-CCM GDSC1 -2.047 -0.5219 -2.291 15.1732
SF295 GDSC1 -2.0107 2.4165 -3.5909 24.0403
D-247MG GDSC1 -1.9754 2.1854 -3.4455 22.9658
D-566MG GDSC1 -1.9331 -1.0232 -2.0063 12.5695
SF268 GDSC1 -1.8275 3.4537 -3.9292 25.188
GI-1 GDSC1 -1.7445 1.9866 -3.1323 19.8328
A-172 GDSC1 -1.7334 1.2257 -2.7524 17.0624
SF126 GDSC1 -1.7162 3.0192 -3.6137 22.8532
GaMG GDSC1 -1.4763 0.4436 -2.1309 11.2195
D-392MG GDSC1 -1.4122 8.4222 -6.0368 32.1454
MOG-G-UVW GDSC1 -1.2969 0.4742 -1.9775 9.2643
D-263MG GDSC1 -1.2935 1.9397 -2.6999 14.812
KALS-1 GDSC1 -1.0832 0.6245 -1.8607 7.4949
GB-1 GDSC1 -1.0019 0.7776 -1.8678 7.2452
SW1783 GDSC1 -0.9987 2.117 -2.5347 12.4292
DK-MG GDSC1 -0.9261 4.5837 -3.7076 20.2355
D283 Med GDSC1 -0.9115 0.3747 -1.5913 4.74
Daoy GDSC1 -0.8661 1.0785 -1.906 7.061
SNB-75 GDSC1 -0.8591 2.4088 -2.565 12.1516
U-251MG GDSC1 -0.8136 2.9859 -2.8163 13.8597
AM-38 GDSC1 -0.6246 2.0377 -2.1935 8.4997
KNS-42 GDSC1 -0.6071 0.7042 -1.5241 3.2613
DBTRG-05MG GDSC1 -0.5896 2.8568 -2.5733 11.2856
SF539 GDSC1 -0.585 0.9511 -1.6284 3.9976
LNZTA3WT4 GDSC1 -0.5232 1.4788 -1.8417 5.4597
SW1088 GDSC1 -0.0975 14.9478 -8.2111 33.3556
M059J GDSC1 -0.0264 9.1342 -5.2558 24.8077
D-502MG GDSC1 -0.0127 2.0223 -1.76 3.5362
LN-229 GDSC1 0.2668 2.6373 -1.8733 3.7316
U-87MG ATCC GDSC1 0.3101 3.8073 -2.3911 7.3146
U-118MG GDSC1 0.4075 3.6274 -2.2437 6.0249
Onda 10 GDSC1 0.4207 3.85 -2.3395 6.6742
D-542MG GDSC1 0.5397 2.0177 -1.467 0.8522
Becker GDSC1 0.6492 5.6461 -3.0419 10.9548
PFSK-1 GDSC1 0.7967 3.3689 -1.9004 2.9291
Onda 11 GDSC1 0.8862 6.8827 -3.4744 13.0873
LN-405 GDSC1 1.14 2.5142 -1.41 0.2651
KINGS-1 GDSC1 1.3317 11.5809 -5.4427 21.7237
KNS-81-FD GDSC1 1.6237 9.4344 -4.1982 15.2959
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1 -1.2437 2.2151 -2.7933 15.3071
TGBC1TKB GDSC1 -0.5018 1.6094 -1.8902 5.7702
TGBC24TKB GDSC1 -0.3674 2.2273 -2.0953 6.9506
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AN3-CA GDSC1 -1.762 2.4208 -3.3611 21.4518
ESS-1 GDSC1 -1.2746 1.5608 -2.4948 13.1843
RL95-2 GDSC1 -1.2091 0.5133 -1.9167 8.4295
EN GDSC1 -1.025 0.5827 -1.7899 6.7166
MFE-296 GDSC1 -0.7542 0.7811 -1.6698 4.8317
MFE-319 GDSC1 -0.4113 2.4659 -2.2444 8.221
KLE GDSC1 -0.3514 2.3781 -2.1575 7.3782
MFE-280 GDSC1 -0.1342 2.1499 -1.897 4.8198
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMRC-20 GDSC1 -3.5565 -3.0611 -3.5565 32.3834
769-P GDSC1 -2.8739 -1.3772 -2.952 24.3524
LB1047-RCC GDSC1 -2.8036 2.7339 -4.5055 32.752
CAL-54 GDSC1 -2.2642 1.2715 -3.2907 23.3414
Caki-1 GDSC1 -2.2103 2.0689 -3.6136 25.1271
UO-31 GDSC1 -2.2056 -0.5353 -2.4568 17.1952
ACHN GDSC1 -1.6121 0.2362 -2.1642 12.0839
OS-RC-2 GDSC1 -1.6014 2.9346 -3.4681 21.446
BFTC-909 GDSC1 -1.5957 1.1585 -2.5897 15.2437
SW156 GDSC1 -1.5936 0.6759 -2.3545 13.4497
VMRC-RCZ GDSC1 -1.5528 0.3033 -2.1376 11.6109
TK-10 GDSC1 -1.5275 3.3183 -3.5922 21.9128
RXF 393L GDSC1 -1.3744 3.2903 -3.4432 20.3382
A-704 GDSC1 -1.3634 0.6301 -2.1152 10.6132
VMRC-RCW GDSC1 -1.2758 0.3231 -1.8838 8.447
LB996-RCC GDSC1 -0.953 2.1788 -2.5275 12.206
HA7-RCC GDSC1 -0.7136 3.2466 -2.8657 13.8655
SN12C GDSC1 -0.3309 2.2999 -2.1045 6.9147
786-O GDSC1 -0.2027 8.1478 -4.9033 23.8842
LB2241-RCC GDSC1 -0.0654 6.7584 -4.1055 19.5375
SW13 GDSC1 -0.0574 2.1787 -1.8608 4.3649
RCC10RGB GDSC1 0.1051 10.5543 -5.8595 26.6584
BB65-RCC GDSC1 0.202 7.065 -4.0543 18.4214
A-498 GDSC1 0.8619 14.8571 -7.4104 29.1574
KMRC-1 GDSC1 0.8911 11.1175 -5.5384 23.2619
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KM12 GDSC1 -3.2341 -1.9357 -3.259 28.5111
COLO205 GDSC1 -2.705 -1.8425 -2.7142 21.7982
HCT 116 GDSC1 -2.4168 -0.3707 -2.7441 20.3518
SW48 GDSC1 -1.9491 1.2514 -2.9719 19.6375
HCT 15 GDSC1 -1.5041 0.519 -2.1936 11.8232
HT115 GDSC1 -1.4308 -0.5825 -1.6122 7.0781
RKO GDSC1 -1.1934 0.6472 -1.969 8.7762
CaR-1 GDSC1 -1.0333 1.2371 -2.124 9.3754
LS180 GDSC1 -0.932 0.9936 -1.9175 7.3831
NCI-H747 GDSC1 -0.8561 0.8819 -1.7999 6.1918
SW948 GDSC1 -0.8382 0.4881 -1.5893 4.4748
HT-29 GDSC1 -0.7593 2.6942 -2.6267 12.2641
SW626 GDSC1 -0.6666 1.759 -2.0876 7.8141
LS411N GDSC1 -0.6307 1.2091 -1.7882 5.3686
MDST8 GDSC1 -0.3668 1.6606 -1.8195 4.8472
HT-55 GDSC1 -0.2968 1.8059 -1.8416 4.8256
LS1034 GDSC1 -0.226 3.9513 -2.8383 12.0574
RCM-1 [Human ESC] GDSC1 -0.2139 1.4578 -1.623 3.0094
NCI-H716 GDSC1 -0.1981 2.4871 -2.1019 6.5203
COLO 678 GDSC1 -0.1207 2.4074 -2.0107 5.6297
LoVo GDSC1 -0.0962 2.5508 -2.0628 5.9536
GP5d GDSC1 0.0115 4.2648 -2.8181 11.1936
SW1417 GDSC1 0.0494 2.889 -2.1269 6.0526
C2BBe1 GDSC1 0.2834 2.5724 -1.8342 3.4295
SW620 GDSC1 0.4625 8.3367 -4.487 19.8923
COLO 320HSR GDSC1 0.4861 2.5879 -1.7283 2.369
T84 GDSC1 0.543 2.5791 -1.6948 2.0754
SNU-C1 GDSC1 0.583 4.8158 -2.6901 8.7381
SW1463 GDSC1 0.6123 2.683 -1.7034 2.023
LS513 GDSC1 0.8002 2.4221 -1.5104 0.8072
HCC2998 GDSC1 0.8409 3.4846 -1.9269 3.0209
CCK-81 GDSC1 1.1412 3.2916 -1.6994 1.3439
CL-11 GDSC1 1.542 3.7665 -1.7092 1.0201
SW837 GDSC1 1.6944 3.5699 -1.5762 0.4626
LS123 GDSC1 1.8397 12.0822 -5.3254 19.9818
CW-2 GDSC1 1.9094 3.8252 -1.5861 0.3956
SNU-C2B GDSC1 2.7627 5.2225 -1.7616 0.4915
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 1.516 3.4229 -1.5919 0.6043
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-387 GDSC1 -2.9804 2.8032 -4.7116 34.5278
SNU-398 GDSC1 -2.9087 14.6086 -10.426 43.7142
JHH-4 GDSC1 -2.8439 -1.3407 -2.9266 24.0074
SNU-449 GDSC1 -2.7499 0.5181 -3.4514 26.9158
SNU-423 GDSC1 -1.9886 2.8876 -3.7995 25.1801
HLE GDSC1 -1.4786 4.3757 -4.0751 24.498
JHH-1 GDSC1 -1.4186 -0.0082 -1.8596 8.8811
JHH-7 GDSC1 -1.3984 5.3409 -4.4865 26.253
SK-HEP-1 GDSC1 -1.132 1.2244 -2.2023 10.3625
JHH-6 GDSC1 -0.9173 -0.0324 -1.3927 3.1959
Hep-G2/C3A GDSC1 -0.2852 4.2524 -3.0316 13.6052
Hep 3B2.1-7 GDSC1 -0.2719 2.239 -2.0332 6.2056
Huh-7 GDSC1 0.0015 2.7241 -2.0803 5.8306
SNU-475 GDSC1 0.1508 2.4467 -1.8557 3.8543
JHH-2 GDSC1 0.2058 3.7993 -2.4568 8.057
HuH-1 GDSC1 0.8558 2.4371 -1.4927 0.6887
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 168 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1755 GDSC1 -4.0725 2.3098 -5.5903 43.3667
A-427 GDSC1 -3.4208 -0.772 -3.7003 32.3851
NCI-H2342 GDSC1 -3.2087 -0.4458 -3.573 30.3172
LC-2/ad GDSC1 -3.1888 -0.1377 -3.6594 30.7081
SW1271 GDSC1 -2.9071 1.7008 -4.131 31.5974
NCI-H2030 GDSC1 -2.7698 -1.2337 -2.8685 23.1876
HCC44 GDSC1 -2.6944 -0.1098 -3.1396 24.5808
HOP-62 GDSC1 -2.6339 -0.2281 -3.03 23.5076
Lu-135 GDSC1 -2.6294 -0.144 -3.0571 23.6672
NCI-H2818 GDSC1 -2.5935 2.2691 -4.0811 29.6665
LXF 289 GDSC1 -2.5601 -0.7817 -2.7593 21.2466
ABC-1 GDSC1 -2.4038 0.6139 -3.1341 22.9954
NCI-H1975 GDSC1 -2.4034 0.0015 -2.8744 21.1942
NCI-H2009 GDSC1 -2.2339 -0.9087 -2.3658 16.7207
LK-2 GDSC1 -2.1705 -1.2743 -2.2109 15.3175
NCI-H647 GDSC1 -2.073 0.5295 -2.7595 18.7005
NCI-H810 GDSC1 -1.9761 6.7771 -5.7084 33.285
UMC-11 GDSC1 -1.9076 1.7396 -3.1658 20.7987
CAL-12T GDSC1 -1.8548 0.7876 -2.6609 16.9394
NCI-H1299 GDSC1 -1.8247 0.2852 -2.3985 14.8437
A-549 GDSC1 -1.8157 -0.1828 -2.1821 13.1931
NCI-H2795 GDSC1 -1.7707 2.1139 -3.2189 20.5425
SK-MES-1 GDSC1 -1.7666 2.6555 -3.4806 22.2436
SBC-3 GDSC1 -1.7037 6.6568 -5.4082 31.2263
NCI-H358 GDSC1 -1.6986 2.3101 -3.2484 20.424
DMS 273 GDSC1 -1.6844 9.7397 -6.9286 35.3757
NCI-H1770 GDSC1 -1.639 -0.9093 -1.7166 8.9283
NCI-H1792 GDSC1 -1.6287 1.0399 -2.5633 15.1886
PC-14 GDSC1 -1.6088 -0.0217 -2.0418 11.1433
COR-L105 GDSC1 -1.607 4.2845 -4.1428 25.3909
LCLC-103H GDSC1 -1.5914 1.6694 -2.8353 17.0496
NCI-H460 GDSC1 -1.5637 -0.7666 -1.6818 8.2724
HCC827 GDSC1 -1.5343 1.7538 -2.8243 16.7251
NCI-H2085 GDSC1 -1.5311 1.7712 -2.8299 16.7522
NCI-H2405 GDSC1 -1.5105 0.2373 -2.0652 10.8679
NCI-H2122 GDSC1 -1.4948 0.0551 -1.964 10.0238
NCI-H650 GDSC1 -1.4833 3.2535 -3.5209 21.2819
LOU-NH91 GDSC1 -1.3751 1.6044 -2.6061 14.4368
Calu-3 GDSC1 -1.3517 9.3032 -6.4253 33.0203
IST-SL2 GDSC1 -1.3463 0.6967 -2.1321 10.6731
NCI-H2170 GDSC1 -1.3071 3.2072 -3.3431 19.4128
NCI-H727 GDSC1 -1.3053 -0.2425 -1.6384 6.6776
SK-LU-1 GDSC1 -1.2995 1.1963 -2.3361 12.0632
NCI-H1648 GDSC1 -1.2711 0.8382 -2.1333 10.3728
NCI-H1563 GDSC1 -1.2371 4.2436 -3.7999 21.9778
LB647-SCLC GDSC1 -1.2293 0.124 -1.7433 7.1583
NCI-H3255 GDSC1 -1.213 1.0789 -2.2008 10.6667
NCI-H2869 GDSC1 -1.2112 0.8549 -2.0879 9.7777
NCI-H2461 GDSC1 -1.1961 -0.0922 -1.6068 5.9564
NCI-H1963 GDSC1 -1.1931 1.8508 -2.5677 13.4187
NCI-H1944 GDSC1 -1.1842 0.8389 -2.0561 9.4215
HCC15 GDSC1 -1.1661 0.9508 -2.0957 9.6603
NCI-H2171 GDSC1 -1.1607 0.0691 -1.6535 6.1738
NCI-H1048 GDSC1 -1.1382 -0.3146 -1.4442 4.4477
NCI-H290 GDSC1 -1.1377 0.88 -2.0356 9.0788
EBC-1 GDSC1 -1.1281 0.785 -1.9799 8.6047
NCI-H847 GDSC1 -1.1001 -0.2063 -1.4626 4.4335
NCI-H2087 GDSC1 -1.0572 0.8399 -1.9459 8.0666
NCI-H1734 GDSC1 -1.0183 1.2774 -2.1314 9.3785
NCI-H3122 GDSC1 -1.0096 0.2968 -1.634 5.4306
RERF-LC-KJ GDSC1 -0.9947 0.9314 -1.9385 7.7759
NCI-H211 GDSC1 -0.9915 0.3134 -1.6269 5.3077
NCI-H1355 GDSC1 -0.9898 1.0406 -1.9891 8.1561
Lu-99A GDSC1 -0.9864 4.5974 -3.7646 20.8016
NCI-H1650 GDSC1 -0.9543 0.6352 -1.7567 6.1962
EPLC-272H GDSC1 -0.9228 1.5845 -2.2052 9.6081
NCI-H2081 GDSC1 -0.9138 0.8003 -1.8059 6.4391
NCI-H292 GDSC1 -0.905 0.9344 -1.8657 6.8795
NCI-H2804 GDSC1 -0.8898 2.112 -2.4418 11.3229
NCI-H1568 GDSC1 -0.8843 1.7132 -2.238 9.7262
NCI-H1793 GDSC1 -0.879 1.4708 -2.1125 8.7277
NCI-H69 GDSC1 -0.8786 2.4418 -2.5975 12.467
NCI-H2369 GDSC1 -0.8692 3.0129 -2.8752 14.4881
NCI-H526 GDSC1 -0.8555 2.2776 -2.4965 11.6182
NCI-H1703 GDSC1 -0.8502 2.1555 -2.4312 11.0997
Lu-134-A GDSC1 -0.8373 1.028 -1.8577 6.5818
NCI-H2722 GDSC1 -0.8343 4.1068 -3.3934 17.929
NCI-H510A GDSC1 -0.784 0.7265 -1.6656 4.8951
NCI-H2141 GDSC1 -0.7576 1.0315 -1.7967 5.8367
BEN GDSC1 -0.7484 5.7143 -4.1265 21.9675
NCI-H2023 GDSC1 -0.7385 1.5576 -2.0434 7.7057
LCLC-97TM1 GDSC1 -0.7108 3.0042 -2.7425 12.9562
NCI-H1304 GDSC1 -0.6813 1.257 -1.8499 6.0075
NCI-H2731 GDSC1 -0.6805 3.0108 -2.7216 12.6973
SBC-5 GDSC1 -0.6586 1.2249 -1.8168 5.6776
NCI-H2228 GDSC1 -0.6203 1.2702 -1.8106 5.5104
IA-LM GDSC1 -0.61 1.2616 -1.7987 5.3865
COLO 668 GDSC1 -0.5304 1.9768 -2.0919 7.4148
IST-SL1 GDSC1 -0.5238 2.27 -2.2317 8.4727
HARA [Human squamous cell lung carcinoma] GDSC1 -0.4989 1.8643 -2.0131 6.7099
NCI-H661 GDSC1 -0.495 1.6188 -1.8898 5.7473
NCI-H2135 GDSC1 -0.4789 1.7187 -1.927 5.9869
NCI-H2172 GDSC1 -0.4058 1.1773 -1.6143 3.4063
NCI-H2803 GDSC1 -0.3928 9.3413 -5.6499 27.4494
NCI-H1869 GDSC1 -0.3781 1.5047 -1.7522 4.3691
NCI-H522 GDSC1 -0.3779 6.4413 -4.1915 21.025
NCI-H2591 GDSC1 -0.376 1.8206 -1.9033 5.5093
HOP-92 GDSC1 -0.3163 6.222 -4.0338 19.965
PaCa-3 GDSC1 -0.2973 2.8851 -2.3665 8.8037
NCI-H1437 GDSC1 -0.2966 1.9147 -1.8937 5.2181
NCI-H1993 GDSC1 -0.2698 2.3028 -2.0627 6.423
NCI-H1781 GDSC1 -0.2607 4.0609 -2.9185 12.7355
HCC78 GDSC1 -0.1987 2.7569 -2.2331 7.5102
NCI-H1436 GDSC1 -0.1398 2.6214 -2.1264 6.5455
NCI-H2029 GDSC1 -0.132 1.3017 -1.5032 2.0049
NCI-H2347 GDSC1 -0.0815 2.9205 -2.2304 7.1643
NCI-H1581 GDSC1 -0.0626 1.8683 -1.7195 3.3594
COR-L23 GDSC1 -0.0371 1.8638 -1.702 3.1797
Lu-165 GDSC1 -0.0249 1.6199 -1.5843 2.3432
NCI-H1915 GDSC1 0.0164 2.553 -1.9894 5.1259
NCI-H1694 GDSC1 0.1223 2.118 -1.723 2.9942
Ms-1 GDSC1 0.17 3.5382 -2.356 7.4195
NCI-H520 GDSC1 0.1742 2.5423 -1.8854 4.0128
NCI-H1693 GDSC1 0.1853 6.0098 -3.547 15.5154
NCI-H64 GDSC1 0.2522 3.5934 -2.3277 7.0036
NCI-H441 GDSC1 0.2703 4.2831 -2.6452 9.2364
NCI-H226 GDSC1 0.279 5.6029 -3.2793 13.5419
NCI-H2196 GDSC1 0.3299 2.3904 -1.7267 2.6258
SHP-77 GDSC1 0.3424 2.5714 -1.7998 3.0833
NCI-H2110 GDSC1 0.4418 3.7512 -2.2799 6.2008
Calu-6 GDSC1 0.443 4.5844 -2.6728 8.9746
NCI-H446 GDSC1 0.4509 3.3637 -2.0947 4.8787
EKVX GDSC1 0.4741 2.8661 -1.8566 3.2123
NCI-H1092 GDSC1 0.4915 2.7042 -1.7758 2.6585
NCI-H2595 GDSC1 0.5106 5.7804 -3.2018 12.3799
NCI-H838 GDSC1 0.5155 4.4522 -2.5621 8.0144
Lu-65 GDSC1 0.5287 2.4053 -1.6289 1.7105
NCI-H1651 GDSC1 0.6399 3.8037 -2.1824 5.0812
Lu-139 GDSC1 0.6912 3.2668 -1.9129 3.1869
NCI-H345 GDSC1 0.7234 1.5687 -1.2348 0.0592
NCI-H748 GDSC1 0.7242 4.4314 -2.4197 6.5298
NCI-H2227 GDSC1 0.7697 4.5451 -2.4443 6.5966
NCI-H82 GDSC1 0.783 2.2502 -1.4525 0.5873
COR-L88 GDSC1 0.7881 4.5381 -2.4297 6.4562
NCI-H1155 GDSC1 0.804 2.4449 -1.5176 0.8344
NCI-H2444 GDSC1 0.8121 2.1259 -1.3953 0.3727
NCI-H1623 GDSC1 0.8169 2.7038 -1.6133 1.2687
NCI-H2373 GDSC1 0.8376 3.9859 -2.1493 4.459
COR-L95 GDSC1 0.8482 2.6771 -1.5885 1.1148
NCI-H1435 GDSC1 0.8959 2.2771 -1.4176 0.3964
NCI-H1838 GDSC1 0.9051 3.6571 -1.9672 3.1656
NCI-H1688 GDSC1 0.9179 2.8978 -1.6444 1.3126
DMS 53 GDSC1 0.9611 4.8135 -2.4513 6.227
NCI-H841 GDSC1 1.0096 8.6601 -4.2483 17.1379
NCI-H1573 GDSC1 1.0184 3.1276 -1.69 1.4295
NCI-H187 GDSC1 1.0376 2.2699 -1.3624 0.1943
NCI-H720 GDSC1 1.0457 2.5967 -1.4752 0.4964
NCI-H196 GDSC1 1.0646 2.5953 -1.4673 0.4598
RERF-LC-Sq1 GDSC1 1.0946 3.7304 -1.9004 2.472
RERF-LC-MS GDSC1 1.173 5.7347 -2.7458 7.7253
NCI-H23 GDSC1 1.2777 2.9686 -1.5198 0.5078
NCI-H1666 GDSC1 1.3064 3.557 -1.73 1.3216
DMS 114 GDSC1 1.3106 2.8045 -1.4489 0.2936
NCI-H524 GDSC1 1.3428 3.3722 -1.6431 0.911
NCI-H1836 GDSC1 1.344 3.0426 -1.5209 0.4752
NCI-H596 GDSC1 1.3545 2.9821 -1.4952 0.3953
NCI-H2291 GDSC1 1.4746 3.3276 -1.5734 0.568
SBC-1 GDSC1 1.526 3.4102 -1.5833 0.5709
NCI-H513 GDSC1 1.575 8.7466 -3.9027 13.832
NCI-H1876 GDSC1 1.6151 3.4821 -1.5749 0.4976
ChaGo-K-1 GDSC1 1.6169 11.4815 -5.1905 19.9704
NCI-H322M GDSC1 1.6595 3.9305 -1.7222 0.9804
NCI-H209 GDSC1 1.6623 3.8847 -1.7038 0.907
LC-1/sq GDSC1 1.7176 5.3232 -2.2558 3.6219
SW1573 GDSC1 1.7406 22.0649 -10.3107 32.8634
HCC33 GDSC1 1.7702 2.9886 -1.3521 0.0497
CPC-N GDSC1 1.786 3.6384 -1.5661 0.3954
DMS 79 GDSC1 1.869 4.0169 -1.6699 0.6543
⏷ Show the Full List of 168 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 0.4069 3.9971 -2.4177 7.2634
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-510 GDSC1 -2.464 -1.284 -2.5262 19.1273
KYSE-270 GDSC1 -2.2455 0.2181 -2.7993 19.8457
T.T GDSC1 -2.1811 0.1612 -2.7082 18.8659
KYSE-450 GDSC1 -2.0127 -0.8828 -2.132 13.8754
TE-11 GDSC1 -1.7997 -0.1847 -2.1647 12.9845
OE21 GDSC1 -1.78 1.4575 -2.9085 18.4098
KYSE-150 GDSC1 -1.7753 0.9777 -2.6736 16.6689
KYSE-410 GDSC1 -1.6608 4.3664 -4.2312 26.0742
TE-15 GDSC1 -1.5978 -0.382 -1.8709 9.8154
KYSE-520 GDSC1 -1.4763 1.0311 -2.4161 13.4115
TE-9 GDSC1 -1.3455 -0.6685 -1.4871 5.7325
COLO 680N GDSC1 -1.2116 0.5672 -1.9457 8.6666
KYSE-180 GDSC1 -1.0906 0.5683 -1.8392 7.3535
KYSE-70 GDSC1 -0.9777 0.9889 -1.9531 7.828
TE-10 GDSC1 -0.8522 0.6773 -1.6947 5.3498
KYSE-140 GDSC1 -0.6925 1.8077 -2.1319 8.2437
OE33 GDSC1 -0.5589 1.0403 -1.6533 4.1138
TE-1 GDSC1 -0.4573 6.5224 -4.295 21.835
TE-6 GDSC1 -0.2635 2.6931 -2.2481 7.81
OE19 GDSC1 -0.2548 1.4814 -1.6597 3.3699
TE-8 GDSC1 -0.0095 3.6813 -2.5486 9.3152
TE-5 GDSC1 0.5605 2.3381 -1.5857 1.4273
EC-GI-10 GDSC1 1.2067 3.2831 -1.6671 1.1294
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TOV-112D GDSC1 -3.0695 -1.4952 -3.1418 26.7571
EFO-21 GDSC1 -2.8178 -0.3874 -3.1699 25.4723
OVTOKO GDSC1 -2.5042 0.138 -3.0362 22.8508
TOV-21G GDSC1 -2.2112 0.5172 -2.8944 20.3507
Kuramochi GDSC1 -1.66 -0.4322 -1.9147 10.4499
A2780 GDSC1 -1.3844 1.3881 -2.5076 13.727
EFO-27 GDSC1 -1.3671 0.2193 -1.9188 9.1079
SK-OV-3 GDSC1 -1.0515 -0.2283 -1.4082 3.8122
OC 314 GDSC1 -1.0021 8.7757 -5.8668 30.1919
OAW42 GDSC1 -0.9871 0.7208 -1.8269 6.8685
Caov-3 GDSC1 -0.8875 0.1267 -1.4482 3.5304
OVCAR-8 GDSC1 -0.8437 0.5935 -1.6462 4.9396
OVCAR-4 GDSC1 -0.7769 1.2569 -1.9239 6.8978
OVCAR-3 GDSC1 -0.7195 1.4276 -1.9639 7.0209
OVCAR-5 GDSC1 -0.6648 5.0834 -3.7434 19.4985
OVISE GDSC1 -0.0485 1.5423 -1.563 2.2459
OAW28 GDSC1 -0.0293 8.2815 -4.834 23.0253
Caov-4 GDSC1 0.1456 5.021 -3.0911 12.687
IGROV-1 GDSC1 0.4809 13.9145 -7.2373 29.6894
FU-OV-1 GDSC1 0.7213 2.4583 -1.5592 1.1053
OVKATE GDSC1 0.9361 2.7041 -1.5605 0.9043
ES-2 GDSC1 1.199 2.5839 -1.4128 0.25
RMG-I GDSC1 1.2908 13.3979 -6.3648 25.1202
TYK-nu GDSC1 1.57 3.0656 -1.4458 0.2027
OV-90 GDSC1 2.7787 14.0687 -5.6379 19.0684
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Panc 03.27 GDSC1 -2.6883 -0.6906 -2.9274 23.1123
KP-4 GDSC1 -1.6459 0.8043 -2.4662 14.5309
Panc 10.05 GDSC1 -1.5588 1.2735 -2.6112 15.2457
MZ-PC-1 GDSC1 -1.4998 2.4104 -3.1172 18.673
HPAC GDSC1 -1.3977 -0.0207 -1.8333 8.5851
BxPC-3 GDSC1 -1.3821 0.4481 -2.0438 10.1393
KP-1N GDSC1 -1.3117 2.1296 -2.8104 15.7036
KP-3 GDSC1 -1.3078 0.8174 -2.1563 10.7019
CFPAC-1 GDSC1 -1.2788 0.3884 -1.9186 8.7304
SUIT-2 GDSC1 -1.0289 0.2647 -1.6344 5.5058
PaTu 8988t GDSC1 -0.8063 0.4783 -1.5596 4.1367
SW1990 GDSC1 -0.7106 0.8622 -1.6768 4.7486
PaTu 8902 GDSC1 -0.7092 0.7268 -1.6089 4.2151
HuP-T4 GDSC1 -0.5417 1.2204 -1.7288 4.644
Panc 04.03 GDSC1 -0.4222 0.9271 -1.5067 2.6521
HuP-T3 GDSC1 -0.3825 1.9212 -1.9568 5.9357
Hs 766T GDSC1 -0.1884 4.3307 -2.9974 13.06
SU.86.86 GDSC1 -0.0499 2.8931 -2.1956 6.8196
MIA PaCa-2 GDSC1 0.0338 1.6589 -1.5685 2.1282
Capan-1 GDSC1 0.0486 4.9228 -3.1134 13.1267
Panc 02.03 GDSC1 0.13 2.4452 -1.8676 3.9844
DAN-G GDSC1 0.2346 5.8023 -3.409 14.5046
PL4 GDSC1 0.3089 4.2079 -2.5829 8.6903
Panc 08.13 GDSC1 0.3548 2.8196 -1.9041 3.763
Capan-2 GDSC1 0.5836 4.3217 -2.4568 7.1118
KP-2 GDSC1 0.5868 3.9043 -2.2608 5.7368
AsPC-1 GDSC1 0.8203 4.0311 -2.1795 4.6933
HPAF-II GDSC1 1.2956 3.1351 -1.5737 0.6798
YAPC GDSC1 1.3414 2.5667 -1.3568 0.1104
PSN1 GDSC1 1.544 3.012 -1.4366 0.1929
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 GDSC1 -1.9587 1.6117 -3.1531 20.9478
MPP 89 GDSC1 -1.3495 2.4732 -3.0147 17.3331
NCI-H2452 GDSC1 -0.5292 2.2152 -2.2087 8.3122
IST-Mes1 GDSC1 -0.2466 2.9181 -2.3459 8.498
NCI-H2052 GDSC1 0.0488 11.633 -6.4409 28.6856
MSTO-211H GDSC1 1.6162 3.4053 -1.5471 0.4183
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU145 GDSC1 -1.7209 1.7047 -2.9729 18.6081
PC-3 GDSC1 -0.979 0.4468 -1.6831 5.7052
VCaP GDSC1 -0.4392 3.1204 -2.5884 10.9074
22Rv1 GDSC1 0.9338 4.843 -2.4813 6.4871
LNCaP clone FGC GDSC1 1.484 3.952 -1.806 1.5009
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1 -0.2198 3.5555 -2.6389 10.5951
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 940.T GDSC1 -5.5902 -0.4897 -6.1501 55.4236
A-431 GDSC1 -2.7083 -0.5251 -3.0038 23.7423
Mel JuSo GDSC1 -2.174 -0.5892 -2.4035 16.6501
IGR-37 GDSC1 -2.1433 0.1394 -2.6597 18.3254
G-361 GDSC1 -2.1183 0.676 -2.8715 19.7281
WM1552C GDSC1 -1.8646 0.3261 -2.4573 15.4721
COLO 792 GDSC1 -1.795 1.8235 -3.1001 19.8345
CHL-1 GDSC1 -1.455 -0.7323 -1.5776 6.9529
IGR-1 GDSC1 -1.4182 0.6422 -2.1721 11.2859
SK-MEL-30 GDSC1 -1.381 0.9484 -2.2876 12.0226
HT-144 GDSC1 -1.333 0.8621 -2.2013 11.1545
A-375 GDSC1 -1.1348 0.4555 -1.8217 7.3883
A2058 GDSC1 -1.0862 3.3116 -3.2056 17.6224
A-388 GDSC1 -1.0337 0.8151 -1.9134 7.7226
RPMI-7951 GDSC1 -0.9535 1.0719 -1.9744 7.9088
G-mel GDSC1 -0.9336 2.2179 -2.5309 12.161
WM35 GDSC1 -0.9326 1.8203 -2.3313 10.6242
SK-MEL-3 GDSC1 -0.851 0.7852 -1.7476 5.7622
LOX-IMVI GDSC1 -0.75 6.9294 -4.735 24.9773
Mel Ho GDSC1 -0.7374 1.7798 -2.1532 8.5586
A101D GDSC1 -0.6396 3.2688 -2.8178 13.2617
IPC-298 GDSC1 -0.5662 1.6883 -1.9763 6.6304
SH-4 GDSC1 -0.5312 3.1192 -2.6584 11.727
MMAc-SF GDSC1 -0.4961 1.3781 -1.7731 4.8531
WM115 GDSC1 -0.4615 3.6761 -2.881 13.1183
WM278 GDSC1 -0.3573 2.3055 -2.1262 7.1575
COLO 800 GDSC1 -0.3056 1.7552 -1.8232 4.7104
WM793 GDSC1 -0.2479 3.6156 -2.6892 11.0491
UACC-62 GDSC1 -0.2268 1.9336 -1.8555 4.7473
451Lu GDSC1 -0.1251 2.1412 -1.8869 4.7223
MZ-MEL-7 GDSC1 -0.0865 4.3979 -2.9547 12.4479
GAK GDSC1 0.0633 1.6095 -1.5307 1.8329
UACC-257 GDSC1 0.121 3.4119 -2.3286 7.3476
SK-MEL-1 GDSC1 0.1596 2.1557 -1.7184 2.8886
MZ-MEL-2 GDSC1 0.4058 11.0887 -5.8915 25.8996
DJM-1 GDSC1 0.4506 3.0185 -1.938 3.8015
SK-MEL-28 GDSC1 0.6699 1.7521 -1.316 0.2184
CP66-MEL GDSC1 0.6717 2.4211 -1.567 1.1976
SK-MEL-2 GDSC1 0.6807 7.2287 -3.7851 15.4986
Hs 938.T GDSC1 0.6936 4.6232 -2.5281 7.3478
HMV-II GDSC1 0.7035 9.3332 -4.799 20.6796
M14 GDSC1 0.7256 3.1002 -1.8223 2.5629
IST-MEL1 GDSC1 0.7439 7.3696 -3.8089 15.4594
VMRC-MELG GDSC1 0.7683 2.2004 -1.44 0.5505
RVH-421 GDSC1 0.9509 2.6061 -1.517 0.7118
CP50-MEL-B GDSC1 1.0371 2.7448 -1.5335 0.7116
COLO 829 GDSC1 1.0452 21.2977 -10.4692 34.4699
MeWo GDSC1 1.0544 2.8583 -1.5692 0.8407
LB373-MEL-D GDSC1 1.058 3.1376 -1.676 1.3178
SK-MEL-24 GDSC1 1.1595 2.5112 -1.4018 0.2392
COLO 783 GDSC1 1.2278 2.5375 -1.3864 0.1855
WT2-iPS GDSC1 1.2297 4.528 -2.1708 3.8885
SK-MEL-5 GDSC1 1.7689 8.0327 -3.4415 10.7434
COLO 679 GDSC1 1.9914 21.3804 -9.7803 31.5224
LB2518-MEL GDSC1 2.0713 11.7367 -4.9989 18.0448
EquiPSC Line K2 GDSC1 1.4876 3.7032 -1.708 1.06
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 -2.9285 -1.7541 -2.955 24.701
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 633.T GDSC1 -4.505 -2.9848 -4.5133 44.2789
SW982 GDSC1 -4.497 -0.1191 -5.08 45.5368
A-204 GDSC1 -3.3277 0.846 -4.1927 34.3503
MES-SA GDSC1 -2.8424 -1.3429 -2.9245 23.9855
HT-1080 GDSC1 -2.4251 -0.846 -2.5926 19.3479
MFH-ino GDSC1 -2.3908 -0.2316 -2.7687 20.385
G-402 GDSC1 -2.3001 3.3936 -4.3375 29.4701
G-401 GDSC1 -2.2125 4.2177 -4.6579 30.5018
VA-ES-BJ GDSC1 -1.9954 0.4191 -2.6313 17.387
SK-UT-1 GDSC1 -1.6884 1.294 -2.7428 16.7917
SK-LMS-1 GDSC1 -1.6327 -0.0002 -2.0757 11.5113
SW872 GDSC1 -1.6235 0.1529 -2.1367 11.9288
STS-0421 GDSC1 -1.3673 2.0336 -2.8119 15.9401
EW-8 GDSC1 -1.1079 -0.0037 -1.5699 5.3051
GCT GDSC1 -1.0687 0.8374 -1.9545 8.1772
KYM-1 GDSC1 -0.5825 0.9344 -1.6185 3.9145
Rh30 GDSC1 -0.4399 5.8743 -3.958 19.9594
RD GDSC1 -0.3871 3.0549 -2.5166 10.2069
Rh41 GDSC1 -0.2906 2.8977 -2.3678 8.7934
SW684 GDSC1 -0.1727 7.9799 -4.7961 23.3102
TE 441.T GDSC1 -0.0084 2.9245 -2.1825 6.6123
RKN GDSC1 2.3496 9.2694 -3.6553 10.7161
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS GDSC1 -2.4496 0.0064 -2.9252 21.7927
HGC-27 GDSC1 -2.32 -1.232 -2.3804 17.3169
GCIY GDSC1 -1.8293 1.9823 -3.2094 20.7401
IM95 GDSC1 -1.7496 0.6072 -2.4731 15.0524
NUGC-4 GDSC1 -1.4945 1.6275 -2.7257 15.8291
MKN1 GDSC1 -1.4553 -0.1771 -1.817 8.7251
ECC12 GDSC1 -1.2463 1.3965 -2.3881 12.2517
RERF-GC-1B GDSC1 -1.2331 0.4037 -1.8844 8.2744
OCUM-1 GDSC1 -0.8705 2.2077 -2.4738 11.4987
Fu97 GDSC1 -0.7849 1.3711 -1.9872 7.421
MKN28 GDSC1 -0.7415 1.2456 -1.8906 6.5196
23132/87 GDSC1 -0.6351 0.8482 -1.6141 4.0332
NUGC-3 GDSC1 -0.5906 1.9644 -2.1311 7.9074
RF-48 GDSC1 -0.502 2.2984 -2.2293 8.3853
ECC10 GDSC1 -0.5002 1.297 -1.7365 4.5849
MKN45 GDSC1 -0.1882 15.9579 -8.7887 34.6363
HSC-39 GDSC1 0.22 1.8463 -1.5499 1.6981
NCI-N87 GDSC1 0.2877 3.646 -2.3294 6.9268
Hs 746.T GDSC1 0.3851 3.077 -2.0031 4.3824
SNU-1 GDSC1 0.3965 3.432 -2.1596 5.455
SNU-5 GDSC1 0.4481 2.2503 -1.6044 1.6829
SCH GDSC1 0.8117 1.8559 -1.3008 0.1394
SNU-16 GDSC1 1.2099 2.5281 -1.3895 0.1969
TGBC11TKB GDSC1 1.2214 2.7955 -1.4791 0.4131
TMK-1 GDSC1 1.3934 3.5439 -1.6871 1.0514
MKN7 GDSC1 1.4404 5.332 -2.4076 5.0024
SNG-M GDSC1 -1.1902 0.4943 -1.8903 8.1464
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ML-1 [Human leukemia] GDSC1 -5.1006 3.1783 -7.0272 50.819
CGTH-W-1 GDSC1 -4.7157 -0.6493 -5.1487 47.5206
TT2609-C02 GDSC1 -3.358 -1.1098 -3.5386 31.0276
IHH-4 GDSC1 -2.7205 -1.7469 -2.737 22.038
8505C GDSC1 -1.8437 1.2213 -2.8558 18.317
B-CPAP GDSC1 -1.6969 2.5137 -3.3469 21.0724
ASH-3 GDSC1 -1.2152 0.6832 -2.0064 9.1556
KMH-2 GDSC1 -1.1394 4.2305 -3.7099 21.0614
CAL-62 GDSC1 -1.044 3.632 -3.3302 18.2969
K5 GDSC1 -0.993 6.269 -4.6059 25.261
BHT-101 GDSC1 -0.4757 2.0487 -2.0866 7.2064
HTC-C3 GDSC1 -0.1806 6.1353 -3.8851 18.6799
FTC-133 GDSC1 0.1091 1.8623 -1.6164 2.3049
WRO GDSC1 0.2526 4.5301 -2.7765 10.2123
8305C GDSC1 0.345 6.8805 -3.8574 16.884
TT GDSC1 0.9614 2.5219 -1.4812 0.5699
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCC-4 GDSC1 -2.1995 -0.7917 -2.3634 16.5113
JHU-011 GDSC1 -2.1908 -0.7386 -2.3709 16.5145
OSC-20 GDSC1 -2.1593 -0.1425 -2.5586 17.6771
KON GDSC1 -2.1388 -0.2606 -2.4894 17.0735
PCI-04B GDSC1 -1.9946 -0.1262 -2.3924 15.6321
HSC-2 GDSC1 -1.9694 1.2316 -2.9823 19.8054
PCI-06A GDSC1 -1.9103 -0.8379 -2.0341 12.6297
NCI-H3118 GDSC1 -1.623 0.0437 -2.086 11.5432
BHY GDSC1 -1.5447 0.1656 -2.0648 11.0195
BICR 31 GDSC1 -1.4536 5.4289 -4.5782 26.9015
HSC-3 GDSC1 -1.4482 -0.2228 -1.7889 8.4801
CAL-33 GDSC1 -1.2729 -0.4269 -1.5202 5.6288
UPCI-SCC-090 GDSC1 -1.2392 3.7387 -3.5496 20.4696
BB30-HNC GDSC1 -1.2028 1.6842 -2.4931 12.8879
DOK GDSC1 -1.1908 1.0468 -2.1653 10.3015
Detroit 562 GDSC1 -1.1774 -0.266 -1.5046 5.084
SCC-15 GDSC1 -1.0486 1.7172 -2.3769 11.403
SCC-9 GDSC1 -0.9986 1.1784 -2.0653 8.7873
KOSC-2 GDSC1 -0.888 3.3308 -3.0496 15.7996
FaDu GDSC1 -0.8553 8.2941 -5.504 28.4542
OSC-19 GDSC1 -0.8357 1.6096 -2.1467 8.844
SCC-25 GDSC1 -0.8209 1.4704 -2.0653 8.1557
JHU-029 GDSC1 -0.8031 2.2969 -2.4636 11.183
PCI-15A GDSC1 -0.7281 1.8352 -2.1735 8.6856
Ca9-22 GDSC1 -0.6172 2.5093 -2.422 10.2328
PCI-30 GDSC1 -0.5604 4.0996 -3.169 15.4637
HO-1-N-1 GDSC1 -0.5584 2.0081 -2.1284 7.7846
SAT [Human HNSCC] GDSC1 -0.5043 1.7957 -1.9833 6.4963
PE/CA-PJ15 GDSC1 -0.5026 2.2321 -2.1971 8.1396
PCI-38 GDSC1 -0.4951 1.8203 -1.9887 6.5102
JHU-022 GDSC1 -0.454 3.6868 -2.8805 13.0902
HO-1-u-1 GDSC1 -0.3785 2.0324 -2.0081 6.3161
LB771-HNC GDSC1 -0.335 1.7586 -1.8449 4.9527
HSC-4 GDSC1 -0.3321 1.0683 -1.5157 2.5079
BICR 78 GDSC1 -0.2519 1.8368 -1.8261 4.592
CAL-27 GDSC1 0.8715 2.6595 -1.5713 1.0116
BICR 10 GDSC1 1.1846 8.2402 -3.9234 14.9259
SKN-3 GDSC1 1.3399 3.8618 -1.8359 1.8042
SAS GDSC1 1.3766 3.2772 -1.5938 0.698
BB49-HNC GDSC1 2.3562 16.8886 -7.2986 25.4022
BICR 22 GDSC1 2.439 16.8883 -7.2389 25.0589
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW1710 GDSC1 -2.7676 -1.4391 -2.8261 22.8968
RT-112 GDSC1 -2.0338 -0.6097 -2.2449 14.7766
BFTC-905 GDSC1 -1.9618 -0.6904 -2.1388 13.6406
TCCSUP GDSC1 -1.744 7.3083 -5.768 32.5604
5637 GDSC1 -1.4592 4.1 -3.9208 23.5689
SW780 GDSC1 -1.4394 1.5178 -2.6215 14.8181
CAL-29 GDSC1 -0.8931 0.5686 -1.6733 5.3218
639V GDSC1 -0.6948 2.8724 -2.664 12.3196
RT-4 GDSC1 -0.6506 1.2897 -1.8428 5.8549
647V GDSC1 -0.3649 1.2422 -1.6181 3.332
HT-1376 GDSC1 -0.3427 5.2476 -3.5697 17.3331
UM-UC-3 GDSC1 -0.3266 3.9977 -2.937 13.0766
J82 GDSC1 -0.2707 2.6975 -2.2554 7.8861
HT-1197 GDSC1 1.2347 2.7227 -1.4482 0.3222
KU-19-19 GDSC1 1.329 2.5577 -1.358 0.1145
T24 GDSC1 1.5289 10.7335 -4.8894 18.882
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KGN GDSC1 -2.9807 3.1443 -4.8718 35.1231
SKN GDSC1 -2.7302 -0.999 -2.8824 23.0491
NT2-D1 GDSC1 -2.4731 1.1236 -3.432 25.316
PA-1 GDSC1 -2.4301 -0.7591 -2.6247 19.5964
LB831-BLC GDSC1 -2.2319 0.3389 -2.8373 20.0482
DoTc2 4510 GDSC1 -1.9181 -0.1054 -2.3214 14.7278
SW954 GDSC1 -1.5356 -0.2024 -1.8861 9.6252
BPH-1 GDSC1 -1.4372 -0.2942 -1.7453 8.0996
SiSo GDSC1 -1.3858 0.4766 -2.0612 10.29
CAL-39 GDSC1 -1.3155 13.9466 -8.7154 37.4781
C-4-I GDSC1 -1.1932 0.4708 -1.8814 8.0888
Ca Ski GDSC1 -1.1327 0.4509 -1.8177 7.3485
DSH1 GDSC1 -1.0809 0.8262 -1.9594 8.2626
MS751 GDSC1 -1.0797 0.0864 -1.5896 5.3484
HeLa GDSC1 -0.8738 1.2478 -1.9968 7.8015
NCC-IT GDSC1 -0.7396 1.6725 -2.1015 8.1631
OVMIU GDSC1 -0.5193 1.8172 -2.0049 6.7087
NEC8 GDSC1 -0.5043 1.3557 -1.768 4.8383
HT-3 GDSC1 -0.3566 1.533 -1.7512 4.3041
SW962 GDSC1 -0.3047 1.6769 -1.7851 4.4221
HEC-1 GDSC1 -0.0894 2.2119 -1.897 4.708
SKG-IIIa GDSC1 -0.0506 2.4537 -1.9862 5.2684
SiHa GDSC1 0.2709 2.5455 -1.8293 3.4213
ME-180 GDSC1 0.3563 2.7361 -1.8656 3.4979
C-33 A GDSC1 0.5946 3.4865 -2.0652 4.3753
OMC-1 [Human cervical carcinoma] GDSC1 0.8243 2.7665 -1.635 1.3694
JEG-3 GDSC1 1.0277 5.9178 -2.9219 9.215
SW756 GDSC1 1.2916 2.9152 -1.4952 0.4254
JAR GDSC1 1.7793 3.3279 -1.4615 0.1775
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Midostaurin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Midostaurin and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Arn-509 DMT81LZ Major Increased metabolism of Midostaurin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Gilteritinib. Acute myeloid leukaemia [2A60] [16]
Coadministration of a Drug Treating the Disease Different from Midostaurin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Midostaurin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [15]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Oliceridine. Acute pain [MG31] [17]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Midostaurin and Ivabradine. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Midostaurin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Midostaurin and Levalbuterol. Asthma [CA23] [20]
Troleandomycin DMUZNIG Major Decreased metabolism of Midostaurin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Midostaurin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [15]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Eribulin. Breast cancer [2C60-2C6Y] [17]
Talazoparib DM1KS78 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [21]
Tucatinib DMBESUA Major Decreased metabolism of Midostaurin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Palbociclib DMD7L94 Moderate Decreased metabolism of Midostaurin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
Cabazitaxel DMPAZHC Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Cabazitaxel. Breast cancer [2C60-2C6Y] [18]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Bosutinib. Breast cancer [2C60-2C6Y] [18]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [22]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [23]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [20]
Revefenacin DMMP5SI Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [24]
Fidaxomicin DMFP6MV Minor Decreased clearance of Midostaurin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [25]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Midostaurin and Pasireotide. Cushing syndrome [5A70] [17]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Osilodrostat. Cushing syndrome [5A70] [18]
Lumacaftor DMCLWDJ Major Increased metabolism of Midostaurin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [15]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Midostaurin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [15]
MK-8228 DMOB58Q Moderate Decreased metabolism of Midostaurin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [15]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Deutetrabenazine. Dystonic disorder [8A02] [26]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Midostaurin and Ingrezza. Dystonic disorder [8A02] [27]
Stiripentol DMMSDOY Moderate Decreased metabolism of Midostaurin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Midostaurin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Tazemetostat DMWP1BH Moderate Increased metabolism of Midostaurin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [15]
Ripretinib DM958QB Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [25]
Boceprevir DMBSHMF Major Decreased metabolism of Midostaurin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [28]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Cobicistat DM6L4H2 Major Decreased metabolism of Midostaurin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [15]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [17]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Midostaurin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [30]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Midostaurin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [15]
Aliskiren DM1BV7W Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [18]
Levamlodipine DM92S6N Moderate Decreased metabolism of Midostaurin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [15]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Midostaurin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [15]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Midostaurin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [15]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Midostaurin and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Naloxegol DML0B41 Minor Decreased metabolism of Midostaurin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [31]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Midostaurin and Denosumab. Low bone mass disorder [FB83] [32]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Midostaurin and Crizotinib. Lung cancer [2C25] [33]
Ceritinib DMB920Z Major Decreased metabolism of Midostaurin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
PF-06463922 DMKM7EW Moderate Increased metabolism of Midostaurin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Midostaurin and Osimertinib. Lung cancer [2C25] [34]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Midostaurin and Selpercatinib. Lung cancer [2C25] [18]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Midostaurin and Lumefantrine. Malaria [1F40-1F45] [25]
Artesunate DMR27C8 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [18]
Idelalisib DM602WT Major Decreased metabolism of Midostaurin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
GDC-0199 DMH0QKA Major Decreased clearance of Midostaurin due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [25]
IPI-145 DMWA24P Moderate Decreased metabolism of Midostaurin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
Arry-162 DM1P6FR Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Arry-162. Melanoma [2C30] [25]
Trametinib DM2JGQ3 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Trametinib. Melanoma [2C30] [18]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Midostaurin and Vemurafenib. Melanoma [2C30] [17]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and LGX818. Melanoma [2C30] [35]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Midostaurin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [18]
Ubrogepant DM749I3 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Ubrogepant. Migraine [8A80] [36]
Rimegepant DMHOAUG Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Rimegepant. Migraine [8A80] [37]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Midostaurin and Panobinostat. Multiple myeloma [2A83] [38]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Midostaurin and Tecfidera. Multiple sclerosis [8A40] [39]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Midostaurin and Siponimod. Multiple sclerosis [8A40] [25]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Midostaurin and Fingolimod. Multiple sclerosis [8A40] [40]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Midostaurin and Ocrelizumab. Multiple sclerosis [8A40] [41]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Midostaurin and Ozanimod. Multiple sclerosis [8A40] [18]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Midostaurin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [15]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Entrectinib. Non-small cell lung cancer [2C25] [25]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Rucaparib. Ovarian cancer [2C73] [17]
MK-4827 DMLYGH4 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [18]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Triclabendazole. Parasitic worm infestation [1F90] [17]
Abametapir DM2RX0I Moderate Decreased metabolism of Midostaurin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [42]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Midostaurin and Macimorelin. Pituitary gland disorder [5A60-5A61] [43]
Lefamulin DME6G97 Major Decreased metabolism of Midostaurin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [44]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Degarelix. Prostate cancer [2C82] [18]
Enzalutamide DMGL19D Major Increased metabolism of Midostaurin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [15]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Relugolix. Prostate cancer [2C82] [18]
Selexipag DMAHSU0 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Selexipag. Pulmonary hypertension [BB01] [18]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Midostaurin and Golimumab. Rheumatoid arthritis [FA20] [45]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Midostaurin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [46]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Midostaurin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [15]
Larotrectinib DM26CQR Moderate Decreased metabolism of Midostaurin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
LEE011 DMMX75K Moderate Decreased metabolism of Midostaurin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [18]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Pitolisant. Somnolence [MG42] [17]
Fostamatinib DM6AUHV Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [47]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [48]
Apixaban DM89JLN Moderate Decreased metabolism of Midostaurin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [18]
Brilinta DMBR01X Moderate Decreased metabolism of Midostaurin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [15]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Lenvatinib. Thyroid cancer [2D10] [17]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Midostaurin and Cabozantinib. Thyroid cancer [2D10] [18]
Elagolix DMB2C0E Moderate Increased metabolism of Midostaurin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [15]
Betrixaban DM2C4RF Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [49]
⏷ Show the Full List of 93 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Carminic acid E00506 10255083 Colorant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydrogenated polyoxyl 40 castor oil E00662 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Midostaurin 25 mg capsule 25 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5702).
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Swaminathan R: Magnesium metabolism and its disorders. Clin Biochem Rev. 2003 May;24(2):47-66.
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
9 Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism. Arch Toxicol. 2021 Jan;95(1):67-78. doi: 10.1007/s00204-020-02884-2. Epub 2020 Oct 6.
10 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
11 FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15;24(56):8259-67. doi: 10.1038/sj.onc.1208989.
12 Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. Toxicol In Vitro. 2009 Sep;23(6):979-85. doi: 10.1016/j.tiv.2009.06.027. Epub 2009 Jun 30.
13 Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28.
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
16 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
17 Canadian Pharmacists Association.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
20 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
21 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
25 Cerner Multum, Inc. "Australian Product Information.".
26 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
27 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
28 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
29 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
31 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
32 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
33 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
36 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
37 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
38 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
39 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
40 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
42 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
44 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
45 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
46 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
47 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
48 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
49 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.